{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:23:56Z","timestamp":1793129036122,"version":"4.5.0"},"reference-count":84,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1s, have transformed cancer care by their extended efficacy, even receiving next-line. Event-free survival 2 (EFS2), progression\/recurrence-free survival 2 (PRFS2) and progression-free survival 2 (PFS2) capture the time from randomization to objective recurrence\/progression or death on the first subsequent therapy, potentially offering a more accurate measure of durable benefit than first-event endpoints. Our aim is to review the magnitude of this benefit and evaluate long-term endpoints as surrogates for overall survival (OS) in immunotherapy for solid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis searched Web of Science, National Institutes of Health Clinical Trials Registry, American Society of Clinical Oncology and European Society of Medical Oncology conference databases from inception until June 12, 2025, for anti-PD-(L)1-based randomized controlled phase II\/III clinical trials (RCTs) in patients with solid malignancies that reported EFS2, PRFS2 or PFS2. HRs comparing ICI and non-ICI arms were pooled using a random-effects meta-analytic approach. Sensitivity analyses and meta-regressions assessed effect modifiers. A linear regression compared EFS2\/PRFS2\/PFS2 and EFS\/disease-free survival (DFS)\/PFS versus OS HRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>47 RCTs met inclusion criteria from 2,078 citations, comprising 58 intervention comparisons (ICs) and 34,973 patients. Non-small cell lung cancer (NSCLC) was the most investigated tumor (17 RCTs). Anti-PD-(L)1s performed generally worse when administered as a subsequent therapy in non-ICI-experienced patients (p&lt;0.05). Early anti-PD-(L)1 use was associated with significantly improved EFS2\/PRFS2\/PFS2 (HR 0.72; 95%\u2009CI 0.68 to 0.76), with consistent findings across curative and recurrent\/metastatic settings, and particularly strong effects in RCTs involving patients with deficient mismatch repair or high microsatellite instability tumors and those with more radiological responses. In 54 ICs reporting both OS and EFS2\/PRFS2\/PFS2 HRs, a strong correlation (R\u00b2=0.74) was observed across all RCTs, and an even stronger 0.86 specifically among patients with NSCLC (22 ICs). Conversely, EFS\/DFS\/PFS presented R\u00b2 0.39 across all RCTs (51 ICs), and 0.65 in NSCLC (21 ICs; p&lt;0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early use of anti-PD-(L)1 therapy is associated with prolonged disease control and may be linked to enhanced responsiveness to subsequent therapies, mostly based on NSCLC data. Additionally, EFS2\/PRFS2\/PFS2 are solid candidate surrogates for OS and could be considered for routine inclusion and prespecified into immunotherapy RCTs to better capture long-term benefit and inform regulatory, clinical, and reimbursement decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024585378.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013072","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T20:35:18Z","timestamp":1764362118000},"page":"e013072","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-675X","authenticated-orcid":false,"given":"Pablo","family":"Jimenez-Labaig","sequence":"first","affiliation":[{"name":"Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK"},{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8492-5195","authenticated-orcid":false,"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"},{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Vall d'Hebron Institut d'Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Martin-Quesada","sequence":"additional","affiliation":[{"name":"Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland"},{"name":"University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[{"name":"Clinical Research Facility, The Royal Free London NHS Hospital, London, UK"},{"name":"Institute of Immunity and Transplantation, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology, University of Milan, Milan, Italy"},{"name":"European Institute of Oncology, IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[{"name":"Center for Dermato-oncology, Department of Dermatology, Eberhard Karls Universitat Tubingen, T\u00fcbingen, Germany"},{"name":"Image-Guided and Functionally Instructed Tumor Therapies, Cluster of Excellence iFIT (EXC 2180), T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Vall d'Hebron Institut d'Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Vall d\u2019Hebron University Hospital, Barcelona, Spain"},{"name":"Vall d'Hebron Institut d'Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J","family":"Harrington","sequence":"additional","affiliation":[{"name":"Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK"},{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026091123004627000_13.11.e013072.1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"2026091123004627000_13.11.e013072.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"2026091123004627000_13.11.e013072.3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet"},{"key":"2026091123004627000_13.11.e013072.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17670-y"},{"key":"2026091123004627000_13.11.e013072.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306"},{"key":"2026091123004627000_13.11.e013072.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer","volume":"13","author":"Inomata","year":"2023","journal-title":"Sci Rep"},{"key":"2026091123004627000_13.11.e013072.7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01050","article-title":"Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences","volume":"9","author":"Yan","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026091123004627000_13.11.e013072.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"2026091123004627000_13.11.e013072.9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2021.01.009","article-title":"The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy","volume":"331","author":"Kwon","year":"2021","journal-title":"J Control Release"},{"key":"2026091123004627000_13.11.e013072.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2026091123004627000_13.11.e013072.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026091123004627000_13.11.e013072.12","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/2767-9764.CRC-23-0340","article-title":"Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination","volume":"3","author":"Simmons","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026091123004627000_13.11.e013072.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101505","article-title":"Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?","volume":"24","author":"Olivier","year":"2022","journal-title":"Transl Oncol"},{"key":"2026091123004627000_13.11.e013072.14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.34085","article-title":"The validity of progression-free survival 2 as a surrogate trial end point for overall survival","volume":"128","author":"Woodford","year":"2022","journal-title":"Cancer"},{"key":"2026091123004627000_13.11.e013072.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70375-4"},{"key":"2026091123004627000_13.11.e013072.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026091123004627000_13.11.e013072.17","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0522"},{"key":"2026091123004627000_13.11.e013072.18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(08)60505-X","article-title":"EQUATOR: reporting guidelines for health research","volume":"371","author":"Altman","year":"2008","journal-title":"The Lancet"},{"key":"2026091123004627000_13.11.e013072.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026091123004627000_13.11.e013072.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2026091123004627000_13.11.e013072.21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015987","article-title":"The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026091123004627000_13.11.e013072.22","unstructured":"R: the r project for statistical computing. Available: https:\/\/www.r-project.org\/ [Accessed 15 Sep 2024]."},{"key":"2026091123004627000_13.11.e013072.23","unstructured":"Xiang Y , Hasegawa K , Zhu H , et al . A randomized, phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab in patients with high-risk, locally advanced, cervical cancer (keynote-a18\/engot-cx11\/gog-3047): results for patients enrolled in asia."},{"key":"2026091123004627000_13.11.e013072.24","doi-asserted-by":"crossref","first-page":"ix113","DOI":"10.1093\/annonc\/mdz438.021","article-title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"2026091123004627000_13.11.e013072.25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","article-title":"Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study","volume":"36","author":"Graff","year":"2025","journal-title":"Ann Oncol"},{"key":"2026091123004627000_13.11.e013072.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"2026091123004627000_13.11.e013072.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"2026091123004627000_13.11.e013072.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"2026091123004627000_13.11.e013072.29","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"key":"2026091123004627000_13.11.e013072.30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026091123004627000_13.11.e013072.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"2026091123004627000_13.11.e013072.32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308"},{"key":"2026091123004627000_13.11.e013072.33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8573","article-title":"PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC","volume":"37","author":"Bradley","year":"2019","journal-title":"JCO"},{"key":"2026091123004627000_13.11.e013072.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"2026091123004627000_13.11.e013072.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00340"},{"key":"2026091123004627000_13.11.e013072.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"2026091123004627000_13.11.e013072.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4"},{"key":"2026091123004627000_13.11.e013072.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"2026091123004627000_13.11.e013072.39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"JCO"},{"key":"2026091123004627000_13.11.e013072.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141"},{"key":"2026091123004627000_13.11.e013072.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2026091123004627000_13.11.e013072.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00274-1"},{"key":"2026091123004627000_13.11.e013072.43","doi-asserted-by":"crossref","first-page":"112941","DOI":"10.1016\/j.ejca.2023.112941","article-title":"Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial","volume":"190","author":"Livingstone","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026091123004627000_13.11.e013072.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02961"},{"key":"2026091123004627000_13.11.e013072.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"2026091123004627000_13.11.e013072.46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"The Lancet"},{"key":"2026091123004627000_13.11.e013072.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.014"},{"key":"2026091123004627000_13.11.e013072.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.006"},{"key":"2026091123004627000_13.11.e013072.49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026091123004627000_13.11.e013072.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017"},{"key":"2026091123004627000_13.11.e013072.51","first-page":"1200","article-title":"Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227","volume":"24","author":"Julie R","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026091123004627000_13.11.e013072.52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2026091123004627000_13.11.e013072.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.019"},{"key":"2026091123004627000_13.11.e013072.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"2026091123004627000_13.11.e013072.55","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026091123004627000_13.11.e013072.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008"},{"key":"2026091123004627000_13.11.e013072.57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"},{"key":"2026091123004627000_13.11.e013072.58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026091123004627000_13.11.e013072.59","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC","volume":"18","author":"de Castro","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026091123004627000_13.11.e013072.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00975"},{"key":"2026091123004627000_13.11.e013072.61","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026091123004627000_13.11.e013072.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02132"},{"key":"2026091123004627000_13.11.e013072.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"2026091123004627000_13.11.e013072.64","doi-asserted-by":"crossref","first-page":"103550","DOI":"10.1016\/j.esmoop.2024.103550","article-title":"43O Durvalumab (D) + carboplatin\/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1\/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O","volume":"9","author":"Trillsch","year":"2024","journal-title":"ESMO Open"},{"key":"2026091123004627000_13.11.e013072.65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02152"},{"key":"2026091123004627000_13.11.e013072.66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"The Lancet"},{"key":"2026091123004627000_13.11.e013072.67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026091123004627000_13.11.e013072.68","first-page":"3475","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"10","author":"Brian I","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091123004627000_13.11.e013072.69","doi-asserted-by":"crossref","unstructured":"Robert J M , konstantin P , Hirotsugu U , et al . Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol 2024;42. doi:10.1200\/JCO.2024.42.16_suppl.4508","DOI":"10.1200\/JCO.2024.42.16_suppl.4508"},{"key":"2026091123004627000_13.11.e013072.70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58674-4"},{"key":"2026091123004627000_13.11.e013072.71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"key":"2026091123004627000_13.11.e013072.72","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01851-x"},{"key":"2026091123004627000_13.11.e013072.73","first-page":"1","article-title":"Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy","volume":"42","author":"Provencio","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026091123004627000_13.11.e013072.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2026091123004627000_13.11.e013072.75","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s43018-022-00497-5","article-title":"Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies","volume":"3","author":"Alouani","year":"2022","journal-title":"Nat Cancer"},{"key":"2026091123004627000_13.11.e013072.76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","article-title":"Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816","volume":"42","author":"Spicer","year":"2024","journal-title":"JCO"},{"key":"2026091123004627000_13.11.e013072.77","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01743-4"},{"key":"2026091123004627000_13.11.e013072.78","doi-asserted-by":"crossref","unstructured":"Borcoman E , Nandikolla A , Long G , et al . Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book 2018;169\u201378. doi:10.1200\/EDBK_200643","DOI":"10.1200\/EDBK_200643"},{"key":"2026091123004627000_13.11.e013072.79","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39116","article-title":"Chemotherapy-Related Toxic Effects and Quality of Life and Physical Functioning in Older Patients","volume":"6","author":"Baltussen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026091123004627000_13.11.e013072.80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026091123004627000_13.11.e013072.81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_201435","article-title":"Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research","volume":"38","author":"Kanesvaran","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026091123004627000_13.11.e013072.82","doi-asserted-by":"crossref","unstructured":"Rizzello E , Leopaldi C , Mass\u00f3 B , et al . Acceptance of progression-free survival 2 (PFS2) by EU5 and Canadian health authorities for cancer drug reimbursement. 2021. Available: https:\/\/www.ispor.org\/docs\/default-source\/euro2021\/20211108rizzello-pfs2-pdf.pdf?sfvrsn=64d66c60_0","DOI":"10.1016\/j.jval.2021.11.896"},{"key":"2026091123004627000_13.11.e013072.83","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2213-2600(23)00052-8","article-title":"Platform trials: the future of medical research?","volume":"11","author":"Burki","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026091123004627000_13.11.e013072.84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184025","article-title":"Time to publication of oncology trials and why some trials are never published","volume":"12","author":"Chapman","year":"2017","journal-title":"PLoS One"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:01:11Z","timestamp":1789192871000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":84,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-013072"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013072","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}